IDH1 and astrocytoma (excluding glioblastoma): To further define the prognostic roles of clinical features, CNS WHO grade, and selected molecular biomarkers in IDH-mutant astrocytoma patients, we assembled a large, clinically well documented patient cohort with long-term follow-up data from the German Glioma Network (GGN) and two institutional cohorts.